NeuroSense Pursues Reverse Split to Avoid Nasdaq Delisting
NRSN is trading near its 52-week low of $0.432 (7.6% above the low).
Summary
NeuroSense Therapeutics is calling a special shareholder meeting on August 26, 2026 to vote on a reverse stock split aimed at regaining Nasdaq compliance, with the board seeking authority to implement a split between 1-for-4 and 1-for-40 within 12 months.
Key Events · Corporate Governance and Compliance · NRSN
-
Reverse Split Proposal
The board is seeking shareholder approval to effect a reverse stock split at a ratio between 1-for-4 and 1-for-40, with the exact ratio and timing left to the board's discretion within 12 months.
-
Nasdaq Delisting Risk
Deficiency notices were received in April 2026 for failing to maintain a $1.00 minimum bid price and $35 million market value; the compliance deadline is September 29, 2026.
-
Authorized Share Capital Impact
The reverse split will effectively increase authorized share capital in proportion to the split ratio, preserving flexibility for future financings.
-
Special Meeting Date
Shareholders will vote on the proposal at a special meeting on August 26, 2026; the record date is July 31, 2026.
Analysis · NRSN · Life Sciences
To regain compliance with Nasdaq's $1.00 minimum bid price and $35 million market value requirements, NeuroSense is asking shareholders to authorize a reverse stock split at a ratio between 1-for-4 and 1-for-40. The board would retain discretion to set the exact ratio and timing within 12 months. Deficiency notices were received in April, and with the stock currently trading at $0.4652—well below the threshold—the September 29, 2026 compliance deadline looms. Should the split fail to win approval and the stock price not recover organically, delisting becomes likely, a scenario that would severely impair liquidity and financing options. The proposal also effectively increases authorized share capital in proportion to the split ratio, preserving the board's ability to issue shares for future capital raises. A special meeting is set for August 26, 2026, giving shareholders a clear near-term catalyst.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRSN was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $0.43 to $1.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.